.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Details for Patent: 5,668,130

« Back to Dashboard

Details for Patent: 5,668,130

Title: Medicament for treating gastrointestinal disorders
Abstract:The use is described of both (i) ranitidine bismuth citrate and (ii) one or more Helicobacter pylori-inhibiting antibiotics in treating or preventing gastrointestinal disorders. Pharmaceutical compositions containing both (i) and (ii) and methods for the preparation of pharmaceutical compositions containing (i) and (ii) are also described.
Inventor(s): McColm; Andrew Alexander (Greenford, GB3)
Assignee: Glaxo Group Limited (GB3)
Filing Date:Jun 05, 1995
Application Number:08/462,583
Claims:1. A method for treating gastrointestinal disorders caused or mediated by H. pylori infections in humans or animals which comprises administering to a human or animal in need thereof an amount of ranitidine bismuth citrate effective against H. pylori in combination with a pharmaceutically acceptable carrier and an amount of amoxycillin effective against H. pylori in combination with a pharmaceutically acceptable carrier, said amoxycillin being administered in relative amounts such that the combination provides a greater than additive effect, said administration being concurrent or nonconcurrent.

2. A method according to claim 1 wherein the gastrointestinal disorder treated is a non-ulcerative one.

3. A method according to claim 1 wherein the gastrointestinal disorder treated is gastritis, non-ulcer dyspepsia, esophagal reflux disease or gastric motility disorder.

4. A method according to claim 1 wherein the gastrointestinal disorder treated is peptic ulcer disease.

5. A method according to claim 1 wherein from 150 mg to 1.5 g of ranitidine bismuth citrate is administered one to four times per day.

6. A method according to claim 5 wherein from 200 to 800 mg of ranitidine bismuth citrate is administered one to four times per day.

7. A method according to claim 1 wherein the administration is concurrent.

8. A method according to claim 7 wherein the ranitidine bismuth citrate and the amoxycillin are administered within one hour of each other.

9. A method according to claim 8 wherein the ranitidine bismuth citrate and the amoxycillin are administered within five minutes of each other.

10. A method according to claim 1 wherein the administration of the ranitidine bismuth citrate and the administration of the amoxycillin are both oral.

11. A method according the claim 1 wherein the ranitidine bismuth citrate is administered orally and the amoxycillin is administered parenterally.

12. A method according to claim 1 wherein the ranitidine bismuth citrate and the amoxycillin are both contained in a twin pack dispenser prior to administration to the human or animal.

13. A method according to claim 1 wherein the administration is nonconcurrent.

14. A method according to claim 1 wherein the ranitidine bismuth citrate is administered for four to eight weeks and the amoxycillin is administered for one to two weeks.

15. A method for treating gastrointestinal disorders caused or mediated by H. pylori infections in humans or animals which comprises administering to a human or animal in need thereof an amount of ranitidine bismuth citrate effective against H. pylori in combination with a pharmaceutically acceptable carrier, an amount of amoxycillin effective against H. pylori in combination with a pharmaceutically acceptable carrier, and an amount of metronidazole effective against H. pylori in combination with a pharmaceutically acceptable carrier, said amoxycillin or said metronidazole being administered in a relative amount such that the combination with ranitidine bismuth citrate provides a greater than additive effect, said administration being concurrent or nonconcurrent.

16. A method according to claim 15 wherein the gastrointestinal disorder is a non-ulcerative one.

17. A method according to claim 15 wherein the gastrointestinal disorder treated is gastritis, non-ulcer dyspepsia, esophagal reflux disease or gastric motility disorder.

18. A method according to claim 15 wherein the gastrointestinal disorder treated is peptic ulcer disease.

19. A method according to claim 15 wherein from 150 mg to 1.5 g of ranitidine bismuth citrate is administered one to four times per day.

20. A method according to claim 15 wherein from 200 to 800 mg of ranitidine bismuth citrate is administered one to four times per day.

21. A method according to claim 15 wherein the administration is concurrent.

22. A method for treating gastrointestinal disorders caused or mediated by H. pylori infections in humans or animals which comprises administering to a human or animal in need thereof an amount of ranitidine bismuth citrate effective against H. pylori in combination with a pharmaceutically acceptable carrier, and an amount of metronidazole effective against H. pylori in combination with a pharmaceutically acceptable carrier, said metronidazole being administered in a relative amount such that the combination with ranitidine bismuth citrate provides a greater than additive effect, said administration being concurrent or nonconcurrent.

23. A method according to claim 22 wherein the gastrointestinal disorder is a non-ulcerative one.

24. A method according to claim 22 wherein the gastrointestinal disorder treated is gastritis, non-ulcer dyspepsia, esophagal reflux disease or gastric motility disorder.

25. A method according to claim 22 wherein the gastrointestinal disorder treated is peptic ulcer disease.

26. A method according to claim 22 wherein from 150 mg to 1.5 g of ranitidine bismuth citrate is administered one to four times per day.

27. A method according to claim 22 wherein from 200 to 800 mg of ranitidine bismuth citrate is administered one to four times per day.

28. A method according to claim 22 wherein the administration is concurrent .
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

How are People Using DrugPatentWatch?

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc